Ranbaxy to get guidance soon for remedial steps on Dewas unit

In May, Ranbaxy hired two US-based consultants to advise it on remedial work to be done at its manufacturing units in India

Drug maker Laboratories is expecting the consultant assessment of its Dewas manufacturing facility, which is under scanner of the US Food and Drugs Administration  (US FDA)  since 2008, to be over by December. The move is significant because the assessment report will provide a definite guidance to the company towards the corrective measures to meet the regulator’s requirements.

In May, hired two US-based consultants to advise it on remedial work to be done at its manufacturing units in India. This was part of a consent decree signed with the US FDA to revoke ban imposed on the company’s various products that were produced in India after it was found guilty of violating the US manufacturing rules.

“Management is working closely with third party experts and US FDA with respect to consent decree. The consultant assessment report for the first phase is expected to by December. After that we will see what needs to be done,” Chief Executive Officer and Managing Director Arun Sawhney told analysts after announcing its earnings for the quarter ended September.

Ranbaxy’s three key Indian facilities at Paonta Sahib and Batamandi (both in Himachal Pradesh) and Dewas (in Madhya Pradesh) have been on the US regulator’s import alert since 2008. The US FDA had banned 30 generic drugs produced by at these three units, citing gross violation of approved manufacturing norms. The regulator had also stopped marketing approval of new products from the company’s Indian facilities after it found violations.

However, after negotiating for over two years, signed a consent decree with the American authorities in December last year, putting an end to the long running regulatory tussle. Though the settlement allowed the company to resume drug imports from India,  it prevents from manufacturing drugs at the Paonta Sahib, Batamandi, Dewas and Gloversville facilities for introduction to the US market and for the President’s Emergency Plan for AIDS Relief (PEPFAR) Programme until drugs can be produced at such facilities in compliance with US manufacturing quality standards.

The Japan’s Daiichi Sankyo owned company had also closed its Gloversville facility in New York in July last year.

According to an analyst, the first phase of the consultant assessment would cover study of Ranbaxy’s Dewas facility and the company is likely to take around two years to implement the corrective measures and get a final approval. “The same at Paonta Sahib may take even longer as the violations there are understood to be even serious,” he added.

Ranbaxy, under the decree, has committed to strengthen procedures and policies to ensure data integrity and to comply with current good manufacturing practices in order to lift ban imposed on its plants in India by the USFDA.

Post the US import alert, has shifted many of its products to its Ohm facility in the US. Recently it has also started expansion in the US to tackle capacity constraints. Besides, the new Mohali unit, which secured US FDA approval late 2011, is also a boost for the company whose US sales suffered for around three  years.

image
Business Standard
177 22
Business Standard

Ranbaxy to get guidance soon for remedial steps on Dewas unit

In May, Ranbaxy hired two US-based consultants to advise it on remedial work to be done at its manufacturing units in India

Sushmi Dey  |  New Delhi 

Drug maker Laboratories is expecting the consultant assessment of its Dewas manufacturing facility, which is under scanner of the US Food and Drugs Administration  (US FDA)  since 2008, to be over by December. The move is significant because the assessment report will provide a definite guidance to the company towards the corrective measures to meet the regulator’s requirements.

In May, hired two US-based consultants to advise it on remedial work to be done at its manufacturing units in India. This was part of a consent decree signed with the US FDA to revoke ban imposed on the company’s various products that were produced in India after it was found guilty of violating the US manufacturing rules.

“Management is working closely with third party experts and US FDA with respect to consent decree. The consultant assessment report for the first phase is expected to by December. After that we will see what needs to be done,” Chief Executive Officer and Managing Director Arun Sawhney told analysts after announcing its earnings for the quarter ended September.

Ranbaxy’s three key Indian facilities at Paonta Sahib and Batamandi (both in Himachal Pradesh) and Dewas (in Madhya Pradesh) have been on the US regulator’s import alert since 2008. The US FDA had banned 30 generic drugs produced by at these three units, citing gross violation of approved manufacturing norms. The regulator had also stopped marketing approval of new products from the company’s Indian facilities after it found violations.



However, after negotiating for over two years, signed a consent decree with the American authorities in December last year, putting an end to the long running regulatory tussle. Though the settlement allowed the company to resume drug imports from India,  it prevents from manufacturing drugs at the Paonta Sahib, Batamandi, Dewas and Gloversville facilities for introduction to the US market and for the President’s Emergency Plan for AIDS Relief (PEPFAR) Programme until drugs can be produced at such facilities in compliance with US manufacturing quality standards.

The Japan’s Daiichi Sankyo owned company had also closed its Gloversville facility in New York in July last year.

According to an analyst, the first phase of the consultant assessment would cover study of Ranbaxy’s Dewas facility and the company is likely to take around two years to implement the corrective measures and get a final approval. “The same at Paonta Sahib may take even longer as the violations there are understood to be even serious,” he added.

Ranbaxy, under the decree, has committed to strengthen procedures and policies to ensure data integrity and to comply with current good manufacturing practices in order to lift ban imposed on its plants in India by the USFDA.

Post the US import alert, has shifted many of its products to its Ohm facility in the US. Recently it has also started expansion in the US to tackle capacity constraints. Besides, the new Mohali unit, which secured US FDA approval late 2011, is also a boost for the company whose US sales suffered for around three  years.

RECOMMENDED FOR YOU

Ranbaxy to get guidance soon for remedial steps on Dewas unit

In May, Ranbaxy hired two US-based consultants to advise it on remedial work to be done at its manufacturing units in India

Drug maker Ranbaxy Laboratories is expecting the consultant assessment of its Dewas manufacturing facility, which is under scanner of the US Food and Drugs Administration  (US FDA)  since 2008, to be over by December. The move is significant because the assessment report will provide a definite guidance to the company towards the corrective measures to meet the regulator’s requirements.

Drug maker Laboratories is expecting the consultant assessment of its Dewas manufacturing facility, which is under scanner of the US Food and Drugs Administration  (US FDA)  since 2008, to be over by December. The move is significant because the assessment report will provide a definite guidance to the company towards the corrective measures to meet the regulator’s requirements.

In May, hired two US-based consultants to advise it on remedial work to be done at its manufacturing units in India. This was part of a consent decree signed with the US FDA to revoke ban imposed on the company’s various products that were produced in India after it was found guilty of violating the US manufacturing rules.

“Management is working closely with third party experts and US FDA with respect to consent decree. The consultant assessment report for the first phase is expected to by December. After that we will see what needs to be done,” Chief Executive Officer and Managing Director Arun Sawhney told analysts after announcing its earnings for the quarter ended September.

Ranbaxy’s three key Indian facilities at Paonta Sahib and Batamandi (both in Himachal Pradesh) and Dewas (in Madhya Pradesh) have been on the US regulator’s import alert since 2008. The US FDA had banned 30 generic drugs produced by at these three units, citing gross violation of approved manufacturing norms. The regulator had also stopped marketing approval of new products from the company’s Indian facilities after it found violations.

However, after negotiating for over two years, signed a consent decree with the American authorities in December last year, putting an end to the long running regulatory tussle. Though the settlement allowed the company to resume drug imports from India,  it prevents from manufacturing drugs at the Paonta Sahib, Batamandi, Dewas and Gloversville facilities for introduction to the US market and for the President’s Emergency Plan for AIDS Relief (PEPFAR) Programme until drugs can be produced at such facilities in compliance with US manufacturing quality standards.

The Japan’s Daiichi Sankyo owned company had also closed its Gloversville facility in New York in July last year.

According to an analyst, the first phase of the consultant assessment would cover study of Ranbaxy’s Dewas facility and the company is likely to take around two years to implement the corrective measures and get a final approval. “The same at Paonta Sahib may take even longer as the violations there are understood to be even serious,” he added.

Ranbaxy, under the decree, has committed to strengthen procedures and policies to ensure data integrity and to comply with current good manufacturing practices in order to lift ban imposed on its plants in India by the USFDA.

Post the US import alert, has shifted many of its products to its Ohm facility in the US. Recently it has also started expansion in the US to tackle capacity constraints. Besides, the new Mohali unit, which secured US FDA approval late 2011, is also a boost for the company whose US sales suffered for around three  years.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard